Akorn Pharmaceuticals Recall 2023
On April 26, 2023, the Akorn Trustee announced that initiated a voluntary recall of various within- expiry human and animal products as a result of itsU.S. facility closures and discontinuation of the Quality activities of these marketed products, ”
 |
| Akorn Pharmaceuticals Recall 2023 |
After declaring bankruptcy two months ago and closing all production sites, Akorn is yanking its products from the market.
Akorn on Wednesday put out a voluntary recall of both its human and animal products, a list that includes more than 70 medications. When the company shut down in February, so too did its quality program, so Akorn can no longer ensure the products work as intended or are safe, it said in a statement.
The company is notifying distributors and asking them to notify customers about the recall. It's also requesting that the recalled products be destroyed.
Akorn called it quits back in February after several years of turmoil. The company tried to sell itself to Fresenius back in 2018, but that deal ended in a courtroom fight and Fresenius walked.
After that, Akorn weathered a series of FDA warning letters, citations and Form 483 filings.
By the time the company closed its doors, it had been “ running at a loss for some time ” and was unable to secure the financing needed to continue operations, CEO Douglas Boothe wrote in a letter to employees earlier this year.
With the bankruptcy, Akorn laid off all of its staffers.
Why did Akorn shut down
Related. By the time the company closed its doors, it had been “running at a loss for some time” and was unable to secure the financing needed to continue operations, CEO Douglas Boothe wrote in a letter to employees earlier this year. With the bankruptcy, Akorn laid off all of its staffers.
What happened to Akorn pharmaceuticals
Akorn Pharmaceuticals (Akorn Operating Company LLC) has filed for Chapter 7 bankruptcy, layed off its entire workforce without severance pay, and closed all its U.S. sites, according to a company letter issued by President and CEO Douglas S. Boothe and posted in the Herald & Review on February 22, 2023.
.jpg "Akorn Pharmaceuticals Recall 2023") |
| Akorn Pharmaceuticals Recall 2023 |
.jpg "Akorn Pharmaceuticals Recall 2023") |
| Akorn Pharmaceuticals Recall 2023 |
